je.st
news
Investment Analysts' Downgrades for November, 28th (ACT, AUE,...
2013-11-29 11:35:04| Biotech - Topix.net
They currently have $172.00 price target on the stock. Zacks' analyst wrote, "Actavis' third quarter EPS of $2.09 was a penny short of the Zacks Consensus Estimate but up 55% y/y.
Tags: november
act
investment
28th
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||